+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 50Years +
All Genders
ID07249216

Molecular Signals in Vitreous Humor Linked to Poor Response to VEGF Inhibitors in Neovascular Age-Related Macular Degeneration

Led by Singapore National Eye Centre · Updated on 2026-09-16

117

Participants Needed

1

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Neovascular age-related macular degeneration nAMD, also known as wet AMD, is a major cause of serious vision loss worldwide. Although treatments that block vascular endothelial growth factor VEGF, such as ranibizumab injections, help many patients, about 20 to 40% do not respond well. This study aims to identify other molecular factors driving the disease in patients who have a suboptimal response by analyzing samples from the eye and comparing good responders to non-responders. All treatment-naive participants will initially receive three monthly injections of ranibizumab. After 12 weeks, their response will be evaluated based on eye fluid and imaging. Patients who respond well will continue with monthly ranibizumab injections for four more months. Those with a suboptimal response will switch to a different treatment, faricimab, given as four monthly injections. This approach helps compare treatments and explore new pathways that might improve care. Participants will have multiple visits over 24 weeks including eye exams and imaging tests to monitor response and collect samples of vitreous humor, the fluid inside the eye. Researchers will measure various biomarkers related to inflammation and blood vessel growth to understand differences between responders and non-responders. The main outcome is the difference in these biomarker levels after 12 weeks. Safety and vision outcomes will also be tracked during the study period.

CONDITIONS

Brief Title

Identification of Molecular Signals in Vitreous Humor Associated With Suboptimal Response to Vascular Endothelial Growth Factor (VEGF) Inhibition in Neovascular Age-related Macular Degeneration (nAMD) Within a Clinical Trial Setting

Research Team

G

Gemmy Cheung

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here